APA (7th ed.) Citation

M, Z., A, A., P, S., J, M., G, S., R, A., . . . B, Y. (2024). Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study. Multiple sclerosis and related disorders, 90, 105790. https://doi.org/10.1016/j.msard.2024.105790

Chicago Style (17th ed.) Citation

M, Zeineddine, et al. "Disease-modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study." Multiple Sclerosis and Related Disorders 90 (2024): 105790. https://doi.org/10.1016/j.msard.2024.105790.

MLA (9th ed.) Citation

M, Zeineddine, et al. "Disease-modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study." Multiple Sclerosis and Related Disorders, vol. 90, 2024, p. 105790, https://doi.org/10.1016/j.msard.2024.105790.